ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements
Transgene Biotek has received ROC approval to extend its 36th AGM deadline by three months. The meeting for FY2025-26 will now be held by December 31, 2026.
Transgene Biotek Ltd announced the resignation of M/s Vasavi & Co. as Statutory Auditors, effective immediately. The auditors cited pre-occupation with other assignments as the reason.
Transgene Biotek submitted its quarterly shareholding pattern for the period ending December 2016. The company noted that certain promoter shares remain in physical form pending listing approval.
Transgene Biotek Limited has appointed M/s Manisha Dubey & Associates as Internal Auditors for a 12-month term. The board approved the appointment during its August 7, 2026 meeting.
Transgene Biotek Ltd reported revenue from operations of ₹0.1 Cr and a net loss of ₹0.4 Cr for Q1 FY27.
Transgene Biotek Limited scheduled a board meeting for August 07, 2026, to consider quarterly financial results and AGM extension.
Transgene Biotek allotted 1,00,00,000 equity shares worth Rs.10 Crore to its promoter on a preferential basis. The allotment converts existing unsecured promoter loans into equity.
Transgene Biotek Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and a net loss of ₹0.5 Cr for Q4 FY26.
Transgene Biotek Ltd reported audited financial results for the year ended March 31, 2026. The company recorded a standalone net loss of ₹1.65 Crore for FY26.
Transgene Biotek Ltd (BSE: 526139) submitted its initial disclosure confirming it does not meet SEBI's 'Large Corporate' criteria for the 2026 financial year. The company reported zero outstanding borrowings as of March 31, 2026. This filing is a routine regulatory compliance matter for listed entities regarding bond market borrowing mandates.
Transgene Biotek Ltd submitted a NIL statement regarding Regulation 32(1) for the quarter ended March 31, 2026. The company confirmed no funds were raised through public, rights, or preferential issues during the period, resulting in no deviation or variation in fund utilization. This is a routine regulatory compliance filing.
Transgene Biotek Ltd submitted a nil compliance report under Regulation 57 of SEBI LODR for the quarter ended March 31, 2026. The company confirmed it has no outstanding non-convertible securities for which interest, dividend, or principal is payable. This is a routine regulatory filing with no material financial impact.
Transgene Biotek Ltd submitted a NIL compliance report under Regulation 57(5) of SEBI LODR. The company confirmed it has no outstanding non-convertible securities and consequently no interest or principal payment obligations for the quarter ended March 31, 2026.
Transgene Biotek Ltd reported a net loss of ₹0.4 Cr for Q3 FY26.